Prevention of haemolytic diseases of the newborn due to anti-D.
D003362:Cost-Benefit Analysis; D004899:Erythroblastosis, Fetal / Q000191:economics / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007518:Isoantibodies; D011247:Pregnancy; D011295:Prenatal Care / Q000191:economics; D012204:Rh-Hr Blood-Group System / Q000276:immunology*
D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System